Schedule II Opioids and Stimulants & CMV Crash Risk and Driver Performance: Evidence Report and Systematic Review

Details

• Creators:
  Brittle, Christine ; Fiedler, Katherine ; Cotterman, Chris
• Corporate Creators:
  Acclaro Research Solutions, Inc.
• Subject/TRT Terms:
  • Motor carriers
  • Commercial vehicles
  • Driver performance
  • Drug use
  • Stimulants
  • Risk assessment
  • Truck crashes
  • Fatalities
  • Literature reviews
• DOI:
  https://doi.org/10.21949/1503006
• Resource Type:
  Tech Report
• Geographical Coverage:
  United States
• Corporate Publisher:
  United States. Department of Transportation. Federal Motor Carrier Safety Administration
• Abstract:
  Driving a large commercial truck is dangerous work. Truck drivers have a fatal work injury ; rate of 22.1 per 100,000 workers, the eighth highest in the nation.1 ; According to the Federal ; Motor Carrier Safety Administration (FMCSA), large trucks were involved in 3,568 fatal ; crashes in 2011, killing 4,108 people and costing the U.S. $39 billion.2 ; The primary mission of the FMCSA is to reduce these crashes, injuries, and fatalities. As a ; part of this mission, its Medical Programs Division works to ensure that commercial motor ; vehicle (CMV) drivers engaged in interstate commerce are physically qualified and able to ; safely perform their work. In order to improve safety the FMCSA commissions systematic ; reviews on a variety of topics. These findings, together with input from FMCSA’s Medical ; Review Board and Medical Expert Panels that are independently convened as needed, are ; used to inform policy and decision-making. ; This systematic review focuses on the effects that licit use of prescribed Schedule II drugs ; have on the risk of CMV crashes or on indirect measures of driver performance. ; Schedule II drugs include a variety of stimulants (such as amphetamine, methamphetamine, ; and methylphenidate), depressants (such as pentobarbital, glutethimide, and phencyclidine), ; and a large number of opioids (including codeine, morphine, hydrocodone, oxycodone, and ; methadone). While these substances have acceptable medical uses, they also carry high ; potential for impairment and abuse. This report focuses specifically on the effects of licit use ; of Schedule II stimulants and opioids.
  More +
• Format:
  PDF
• Funding:
  DTMC75-13-R-00007
• Download URL:
  https://rosap.ntl.bts.gov/view/dot/199/dot_199_DS1.pdf
• File Type:
  [PDF - 1.83 MB]
• Collection(s):
  Federal Motor Carrier Safety Administration
• Main Document Checksum:
  urn:sha256:482db34126e5b6cc0b2d5664792a6c2892644a50ab4ff42d0d7183eca0474443